CD19 CAR-T cell therapy (Chongqing Precision Biotech)

CD19 CAR-T细胞疗法（重庆精准生物技术）

Report date: 2024/11/14 17:32:38

Base Information

Drug NameCD19 CAR-T cell therapy (Chongqing Precision Biotech)
Drug Alias NameLstCAR019(Chongqing Precision Biotech)Anti-CD19 chimeric antigen receptor T cell therapy (Chongqing Precision Biotech)Anti-CD19 CAR-T cell therapy (Chongqing Precision Biotech)CD19-targeted CAR-T Therapy(Precision Biotechnology)CD19 Targeting Chimeric Antigen Receptor T Lymphocytes (CAR-T) Therapy(Precision Biotechnology) +[7] 
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapy
Mechanisms of ActionAnti-CD19T lymphocyte replacements
TargetsB-lymphocyte antigen CD19
Therapy Area/IndicationsScleroderma, SystemicLupus Erythematosus, SystemicAnti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis +[14] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaPhase 2 Clinical
Originator CompaniesChongqing Precision Biotechnology Co Ltd
China Registration ClassClass 1 therapeutic biologic in China

Develop Information

Active CompaniesChongqing Precision Biotechnology Co Ltd
Inactive CompaniesN/A
Active IndicationsScleroderma, SystemicLupus Erythematosus, SystemicAnti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis +[14] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A